The Chulabhorn Royal Academy (CRA) announced an official agreement with ZP Therapeutics, a division of Zuellig Pharma on the supply and distribution of eight million doses of the COVID-19 Vaccine Moderna in Thailand. Aimed for use as prime and booster vaccination, if and when approved, a portion of the vaccines will be allocated to people from vulnerable and underprivileged groups. The first shipment of the vaccines is anticipated to be delivered during the first quarter of 2022.

Professor Nithi Mahanonda, MD., Secretary-General of Chulabhorn Royal Academy, said, "The Chulabhorn Royal Academy has been working closely with the government and related private organizations to combat the ongoing pandemic by offering more vaccine options to the general public, business corporations, vulnerable groups and underprivileged people amidst the emergency situation. The Academy also focuses on conducting research studies of COVID-19 vaccines in Thailand and plans to concurrently conduct systematic research to confirm the immune response results in the country's environment, starting from the end of this year.”

"This collaboration with Zuellig Pharma is an important mission that marks our continued efforts to ensure the inclusivity of vaccine distribution and to drive Thailand's economic recovery. Guided by the aspiration of Professor Dr. Her Royal Highness Princess Chulabhorn Krom Phra Srisavangavadhana, Chancellor of Chulabhorn Royal Academy, we remain committed to equitably providing the public with quality medical services for all,” added Professor Nithi.

Sunaiyanaa Kidkasetpaisal, General Manager, ZP Therapeutics, Zuellig Pharma Thailand, said, "We are honoured to be collaborating with the Chulabhorn Royal Academy in increasing access to the COVID-19 Vaccine Moderna. As the official partner of Moderna in Thailand, ZP Therapeutics draws upon our unparalleled commercialisation capabilities, expertise, and experience to support Thailand's vaccination programmes. In particular, being future-ready to provide protection against new variants of concern with supportive clinical data and when approved by the local authorities."

Similar to its previous COVID-19 vaccine procurements, the Chulabhorn Royal Academy will also work with the Ministry of Public Health in allocating a portion of the COVID-19 Vaccine Moderna to interested business corporations. The central nationwide vaccine price, inclusive of vaccination insurance, will be announced in due course.

Zuellig Pharma provides world-class distribution, digital and commercial services to over 350,000 medical facilities and its more than 1,000 clients, including the top 20 pharmaceutical companies globally. With over 70 years of experience in Thailand, the company is equipped with global standard warehouses and cold chain capacity of more than 40,000 sqm, and distributes more than 80% of the nation's vaccines today.

About Chulabhorn Royal Academy

Chulabhorn Royal Academy adheres to the philosophy of "Be Excellent for Lives". One of the Academy's missions is to promote our institution to be organizational excellence in grooming students and personnel in the fields of science and medicine so that they are able to think critically, generate new knowledge, conduct related research, and apply the knowledge to the real situations. Furthermore, with ethics and humanitarian in mind, they are able to provide the public with quality medical services for all. At the institute, unity and willingness to contribute for the cause of the institute and the country are also observed. Their selfless devotion and acquired characters will eventually benefit all Thai citizens. These core values - providing knowledge and fostering morals - are upheld by the institute. Both are indispensable aspects of such an institute par excellence as the Chulabhorn Royal Academy.